Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation (NASDAQ: INCY) to distribute tafasitamab and pemigatinib (Pemazyre) in Latin America. Related:   Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada.

Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America

Incyte's (INCY) going gets good with another FDA approval - Jakafi for the treatment of chronic GVHD. However, the stock witnesses a decline despite the recent approvals.

Incyte (INCY) Jakafi Wins FDA Approval for Chronic GVHD

MONTREAL, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute tafasitamab (sold as Monjuvi® in the United States and Minjuvi® in Europe) and pemigatinib (Pemazyre®) in Latin America. Under the terms of the agreement, Incyte will be responsible for the development, manufacture and supply to Knight of tafasitamab and pemigatinib, and Knight will be responsible for seeking the necessary regulatory approvals and distributing both medicines in Latin America.

Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America

The FDA has approved Incyte Corporation's (NASDAQ: INCY) approved Jakafi (ruxolitinib) for chronic graft-versus-host disease (GVHD). The approval comes for adult and pediatric patients 12 years and older with GVHD after the failure of one or two lines of systemic therapy.

Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHD

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi® (ruxolitinib) for treatment of chronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. “GVHD is the leading cause of morbidity and mortality in patients following an allogeneic stem cell transplant, yet there historically have been limited treatment options availabl

Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Facebook, Incyte Fall Despite the Nasdaq's Strong Wednesday Start

Incyte (INCY) obtains FDA approval for the cream formulation of ruxolitinib for the treatment of mild to moderate atopic dermatitis.

Incyte (INCY) Ruxolitinib Cream Wins FDA Nod for Atopic Dermatitis

Shares of Incyte Corp. INCY, +0.20% were down 4.0% in premarket trading on Wednesday, the day after the company announced that the Food and Drug Administration had approved Opzelura as a treatment for some patients with mild to moderate atopic dermatitis. The FDA approval for the topical drug came with a warning for serious adverse events - also referred to a black-box warning - that is consistent with oral JAK inhibitors, according to Mizuho Americas analysts.

Incyte gets FDA approval for atopic dermatitis drug

The FDA has approved Incyte Corporation's (NASDAQ: INCY) Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD). Also Read:  FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know.

Incyte's Topical JAK Inhibitor Scores FDA Approval For Atopic Dermatitis

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)

Health Canada has given conditional approval to Incyte Corporation's (NASDAQ: INCY) Pemazyre (pemigatinib) to treat cholangiocarcinoma. Cholangiocarcinoma is a type of cancer that forms in the slender tubes (bile ducts) that carry the digestive fluid bile.

Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada

MADISON, Wis.--(BUSINESS WIRE)--Nimble Therapeutics, a biotechnology company revolutionizing the discovery and development of peptide therapeutics, today announced their strategic research collaboration with Incyte (NASDAQ: INCY) has been expanded to include discovery of additional novel peptide therapies. “Nimble looks forward to building upon on the already strong collaboration between the Nimble and Incyte scientific teams. The expansion of the collaboration serves as yet another important v

Nimble Therapeutics and Incyte Expand their Strategic Research Collaboration to Discover Additional Novel Peptide Therapeutics

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EADV--Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

Johnson & Johnson

JPMorgan Chase & Co

Tesla

Vertex Pharmaceuticals

According to Wall Street legend, a young person approached one of the top businessmen in the U.S. (said to be J.P. Morgan, the founder of his namesake bank J.P.

Insider Buying at These Biotech Companies Indicates Value

Insider Buying at These Biotech Firms Indicates Value

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Incyte (INCY) Down 0.4% Since Last Earnings Report: Can It Rebound?

We believe that the stock price of Incyte, a global biopharmaceutical company, is undervalued at current levels of $75. INCY stock is down 21% over the last-twelve months period, despite revenue increasing 17% over the same period.

Should You Buy Incyte Stock Around $75 Levels?

Morphosys AG - ADR

Incyte (INCY) and partner MorphoSys obtain approval for tafasitamab for adult patients with relapsed or refractory diffuse large B-cell lymphoma by the European Commission.

Incyte (INCY), MorphoSys Win EC Approval for Lymphoma Drug

The European Commission (EC) has granted conditional approval to Incyte Corporation (NASDAQ: INCY) - MorphoSys AG's (NASDAQ: MOR) Minjuvi (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval covers Minjuvi combined with lenalidomide, followed by Minjuvi monotherapy, for DLBCL patients who are not eligible for autologous stem cell transplant (ASCT).

Incyte - MorphoSys's Diffuse Large B-Cell Lymphoma Drug Wins European Approval

WILMINGTON, Del. & PLANEGG, Germany & MUNICH--(BUSINESS WIRE)---- $INCY--Incyte Announces the European Commission Approval of Minjuvi (tafasitamab) Plus Lenalidomide as Treatment for Adults with Relapsed or Refractory DLBCL

Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte Corporation (NASDAQ: INCY) and InnoCare have entered into a collaboration and license agreement to develop and commercial tafasitamab in Greater China. Under the terms of the agreement, InnoCare will pay $35 million upfront.

Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China

WILMINGTON, Del. & BEIJING--(BUSINESS WIRE)---- $INCY--Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China

Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China

Incyte Corp is a biopharmaceutical company conducting both commercial and clinical development operations.

Incyte: Undervalued And Expecting FDA Feedback In H2 2021

There's definitely already a crowded market for PD-1 and PD-L1 immunotherapies.

Is the PD-(L)1 Party Over After Incyte's FDA Rejection?

ACADIA Pharma

Booking Hlds

Earnings season is winding down. With that come analyst projections for where these stocks and the market in general could go in the coming months.

News for Incyte Stock (INCY)